yep to be honest I am a bit stunned, as I never thought OPFS was the endpoint.
http://www.biomedcentral.com/1471-2407/14/897
can see here it states primary endpoint is PFS, same as on the trial site. It does state that PFS in the liver is secondary, so perhaps that implies that OPFS is the primary endpoint? would appreciate comments on this.
Thanks
Clinical Trial Objectives, page-2
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |